Evariste Technologies

Evariste Technologies is a private, preclinical-stage biotech applying advanced mathematical modeling and machine learning to discover and develop small molecule drugs for synthetic lethal oncology indications. Its core asset is the Frobenius AI platform, which integrates multi-omic data for novel target identification and employs machine learning for efficient small molecule design and optimization. The company has built an early pipeline featuring programs against targets like PKMYT1 and VRK1, and is led by a team with expertise in drug discovery, AI, and mathematics.

Frobenius AI platform for synthetic lethal drug discovery. It comprises two main modules: 1) Target Identification, which analyzes multi-omic data to discover novel synthetic lethal targets and biomarkers, and 2) Discovery, which uses machine learning models (optimized for small, noisy datasets) for trillion-compound virtual screening, hit identification, and multi-parameter optimization of small molecules for potency, selectivity, and PK.

Evariste competes in the crowded AI-drug discovery space with companies like Exscientia, Recursion, Relay Therapeutics, and BenevolentAI, many of which also have oncology pipelines. It specifically competes in synthetic lethality with firms targeting pathways like PKMYT1 (e.g., Repare Therapeutics with its PKMYT1 inhibitor) and others exploring novel synthetic lethal interactions. Its differentiation hinges on its proprietary algorithms for target discovery and its focus on small, noisy dataset optimization.